HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management

International Journal of Drug Policy

Volumn 18, Issue 5, 2007, Pages 426-432

  Lazarus, Jeffrey V ^a,b   Shete, Priya B ^c   Eramova, Irina ^a   Merkinaite, Simona ^d   Matic, Srdan ^a  

^a WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

^b LUND UNIVERSITY   (Sweden)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Central and Eastern European Harm Reduction Network   (Lithuania)

Author keywords

Europe; Hepatitis; HIV; Treatment

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COMMUNITY CARE; COUNSELING; EASTERN EUROPE; HEALTH CARE COST; HEALTH EDUCATION; HEALTH PROGRAM; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHYSICIAN; POPULATION RISK; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PUBLIC FIGURE; PUBLIC HEALTH SERVICE; STANDARD; SUPERINFECTION; VACCINATION; WORLD HEALTH ORGANIZATION;

ANTIVIRAL AGENTS; EUROPE, EASTERN; HARM REDUCTION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; NEEDLE-EXCHANGE PROGRAMS; PATIENT EDUCATION; PRACTICE GUIDELINES; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL HEPATITIS VACCINES; WORLD HEALTH ORGANIZATION;

EID: 34548485320     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2007.01.011     Document Type: Article

References (27)

1. Alberti A., Clumeck N., Collins S., Gerlich W., Lundgren J., Palu G., et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. Journal of Hepatology 42 (2005) 615-624
2. Alter M.J. Epidemiology of viral hepatitis and HIV co-infection. Journal of Hepatology 44 1 (2006) S6-S9
3. Central and Eastern European Harm Reduction Network (CEEHRN). (2006). Hepatitis C among drug users in the new EU member states and neighbourhood: Recommendations for action 2006. Retrieved October 18, 2006, from http://www.ceehrn.org/EasyCEE/sys/files/Hep%20C%20FACT%20SHEET%202006%2007%20en.pdf
4. Central and Eastern European Harm Reduction Network (CEEHRN). (2007). Results of mapping of situation with hepatitis C (HCV) among drug users in countries of Central and Eastern Europe (CEE).
5. Donoghoe M.C. Injecting drug use, harm reduction and HIV/AIDS. In: Matic S., Lazarus J.V., and Donoghoe M.C. (Eds). HIV/AIDS in Europe: Moving from death sentence to chronic disease management (2006), World Health Organization Regional Office for Europe, Copenhagen 43-66
6. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2004a). Annual report 2004: The state of the drugs problem in the European Union and Norway. Retrieved July 24, 2006, from http://ar2004.emcdda.europa.eu
7. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2004b). EMCDDA Mongraphs 7: Hepatitis C and injecting drug use: Impact, costs and policy options. Retrieved December 12, 2006, from http://www.emcdda.europa.eu/?nnodeid=428
8. Highleyman, L. (2002) Sexual transmission of hepatitis C. Hepatitis C support project fact sheet. Retrieved December 12, 2006, from http://www.hcvadvocate.org/hepatitis/factsheets_pdf/sextrans.pdf
9. International Harm Reduction Development Program/Open Society Institute (IHRD/OSI). (2006). Harm reduction developments 2005: Countries with injection-driven HIV epidemics. Retrieved December 15, 2006, from http://www.soros.org/initiatives/health/focus/ihrd/articles_publications/publications/ihrdreport_20060417/ihrd_ar.pdf
10. Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization. (2006). AIDS Epidemic update December 2006. Geneva: UNAIDS.
11. Konopnicki D., Mocroft A., de Wit S., Antunes F., Ledergerber B., Katlama C., et al. Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 19 6 (2005) 593-601
12. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis 11 2 (2004) 97-107
13. Michielsen P., and Bottieau E. Therapy of chronic hepatitis C in the setting of HIV co-infection. Acta Gastro-Enterologica Belgica 68 1 (2005) 86-91
14. Palella Jr. F.J., Baker R.K., Moorman A.C., Chmiel J.S., Wood K.C., Brooks J.T., et al. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. Journal of Acquired Immune Deficiency Syndromes 43 1 (2006) 27-34 [electronic version]
15. Rhodes T., Platt L., Maximova S., Koshkina E., Latishevskaya N., Hickman M., et al. Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: A multi-city study. Addiction 101 (2006) 252-266
16. Rizzetto M. Treatment of hepatitis C virus genotype 2 and 3 with pegylated interferon plus ribavirin. Journal of Hepatology 42 2 (2005) 275-276 [author reply 276-277]
17. Robaeys G., Van Vlierberghe H., Mathei C., Van Ranst M., Bruckers L., and Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. European Journal of Gastroenterology and Hepatology 18 2 (2006) 159-166
18. Salmon D., Robain M., Rockstroh J.K., and Benhamou Y. Therapeutic management of hepatitis and HIV infection in coinfected patients: Results of a survey performed before the 2005 Consensus Conference. Journal of Hepatology 44 S1 (2006) S2-S5
19. Smit C., Geskus R., Walker S., Sabin C., Coutinho R., Porter K., et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 20 5 (2006) 741-749
20. Stöver H., and Lines R. Silence still = death: 25 years of HIV/AIDS in prisons. In: Matic S., Lazarus J.V., and Donoghoe M.C. (Eds). HIV/AIDS in Europe: Moving from death sentence to chronic disease management (2006), World Health Organization Regional Office for Europe, Copenhagen 67-85
21. Swan T. Evaluating and deconstructing barriers to HCV treatment for co-infected drug users. European AIDS Treatment News 15 1 (2006) 28-31
22. United Nations Office on Drugs and Crime, World Health Organization, Joint United Nations Programme on HIV/AIDS (UNODC, WHO, & UNAIDS). (2006). HIV/AIDS prevention, care, treatment and support in prison settings: A framework for an effective national response. Vienna: UNODC.
23. Van Thiel D.H., Anantharaju A., and Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. American Journal of Gastroenterology 98 10 (2003) 2281-2288
24. World Health Organization (WHO). (2000a). Fact sheet no. 204: Hepatitis B. Retrieved October 12, 2006, from http://www.who.int/mediacentre/factsheets/fs204/en
25. World Health Organization (WHO). (2000b). Hepatitis C. In Viral cancers. Retrieved October 12, 2006, from http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html
26. World Health Organization (WHO) Regional Office for Europe. (2006a). Management of hepatitis B and HIV coinfection: Clinical protocol for the WHO European region. Copenhagen: WHO. Retrieved October 12, 2006, from http://www.euro.who.int/Document/SHA/HEP_B.pdf
27. World Health Organization (WHO) Regional Office for Europe. (2006b). Management of hepatitis C and HIV coinfection: Clinical protocol for the WHO European region. Copenhagen: WHO. Retrieved October 12, 2006, from http://www.euro.who.int/Document/SHA/HEP_C.pdf